Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?

Moderna reports key cancer trial results, while BioNTech offers financial flexibility and a wider oncology pipeline. Investors weigh Moderna's clinical data against BioNTech's multiple growth paths. Stock prices as of Sept. 11, 2026.

Moderna Singapore's Spikevax XFG, targeting the XFG variant of COVID-19, received authorization from Singapore's Health Sciences Authority. The vaccine uses mRNA technology and is approved for individuals aged six months and older. According to Moderna, this authorization highlights the need for evolving COVID-19 prevention strategies as the virus changes.

The FDA approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults 50+. It's now available at 13,000+ US locations. The vaccine showed 27% higher effectiveness in Moderna's study. It received standard approval for 50-64 and accelerated approval for 65+ with post-marketing study conditions.

Merck and Moderna reported positive Phase 3 trial results for their personalized mRNA vaccine, intismeran autogene (mRNA-4157), combined with pembrolizumab, showing longer recurrence-free survival in high-risk melanoma patients. The vaccine is tailored to each patient's tumor mutations. Detailed data and regulatory review are pending. Accessibility in regions like India may be challenging due to high costs and infrastructure needs.

Moderna has started a Phase 1 trial in Canada for its mRNA-1469 vaccine candidate targeting the Bundibugyo strain of Ebola. The trial, supported by CEPI, will enroll 80 people to assess safety and immune response, not efficacy. No results are available yet. This is one of two Bundibugyo-specific vaccine candidates in human testing, with the other developed by the University of Oxford and the Serum Institute of India.

AMD's shares surged 10%, reaching a $1 trillion market cap, driven by AI chip demand. Meta's Muse AI app boosted its stock. Moderna rallied 30% on cancer vaccine data. Akamai gained 15% after a $11.6B deal with Anthropic. Treasury yields hit 19-year highs, testing rally staying power.